Eli Lilly and Company (LLY)
Why Eli Lilly Was Such a Healthy Stock Today
The pharmaceutical giant's weight loss medication Zepbound was in the spotlight again Tuesday.
LLY: Legal Battle Over FDA's Decision on Eli Lilly's Weight Loss Drug
The Outsourcing Facilities Association, representing companies producing generic versions of Eli Lilly's (LLY, Financial) weight loss drug, has filed a lawsuit against the U.S. Food and Drug Administration (FDA) in a Texas federal court. The group claims that the FDA's decision to remove Eli Lilly's drug from the shortage list was "arbitrary, capricious, and unlawful.
Billion-Dollar News for Eli Lilly Stock Investors
Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.
Compounding group sues FDA for removing Lilly's weight loss drug from shortage list
A drug compounding industry group on Monday sued the U.S. Food and Drug Administration over its decision to take Eli Lilly's blockbuster weight loss and diabetes drugs from its shortage list last week, a move expected to curtail compounding facilities' ability to sell their own versions of the drugs.
5 Large Drug Stocks to Watch From a Thriving Industry
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.
Eli Lilly (LLY) Rises But Trails Market: What Investors Should Know
Eli Lilly (LLY) concluded the recent trading session at $887.16, signifying a +0.18% move from its prior day's close.
The Big 3: LLY, CVX, RBLX
Today's Big 3 dives into medical, energy and digital entertainment names. @ProsperTradingAcademy's Mike Shorr joins Rick Ducat and Nicole Petallides to break down the technical trends in Eli Lilly (LLY), Chevron (CVX), and Roblox (RBLX).
Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant
Lilly is investing $4.5 billion to build a new site for improving manufacturing and drug development.
LLY Outlook Crucial After Mounjaro, Zepbound Shortage Ends
Lee Brown with Third Bridge argues that demanding expectations are built into Eli Lilly's (LLY) stock following a "monstrous" 2Q earnings report. Mounjaro and Zepbound no longer on short supply helps the outlook, but Lee looks into other headwinds facing the pharmaceutical company, including the ILA Union's port worker strike.
Are Medical Stocks Lagging Eli Lilly (LLY) This Year?
Here is how Eli Lilly (LLY) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.
Eli Lilly's weight-loss and diabetes drugs are no longer in shortage, says FDA
The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in expanding manufacturing.
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.
